|By PR Newswire||
|March 21, 2014 05:39 PM EDT||
LONDON, March 21, 2014 /PRNewswire/ --
On Thursday, March 20, 2014, the NASDAQ Composite ended at 4,319.29, up 0.27%, the Dow Jones Industrial Average gained 0.67% to reach 16,331.05, and the S&P 500 closed at 1,872.01, up 0.60%. The gains were broad based as nine of ten sectors finished higher. The S&P 500 Health Care Sector Index finished the day 0.02% lower at 686.29, whereas, the index has advanced 0.77% in the last one month. Investor-Edge has initiated coverage on the following equities: IntelliPharmaCeutics International Inc. (NASDAQ: IPCI), Delcath Systems Inc. (NASDAQ: DCTH), Valeant Pharmaceuticals International Inc. (NYSE: VRX) and Alkermes PLC (NASDAQ: ALKS). Free technical research on IPCI, DCTH, VRX and ALKS can be downloaded upon signing up at:
Shares in IntelliPharmaCeutics International Inc. recorded a trading volume of 1.42 million shares, as compared with a three months average volume of 0.63 million shares. The stock finished the day at $4.79, up 9.11% after trading between $4.34 and $4.83. IntelliPharmaCeutics International Inc.'s shares have surged 11.66% in the previous three trading sessions, 27.93% in the last one month, and 29.11% on YTD basis. The company's shares are trading above their 50-day and 200-day moving averages of $3.95 and $2.69, respectively. Additionally, shares of the company are trading at a Relative Strength Index (RSI) of 59.87. Sign up today to read free research on IPCI at:
Delcath Systems Inc.'s shares recorded a trading volume of 19.28 million shares, as compared with a three months average volume of 4.66 million shares. The stock ended the day at $0.35, up 0.20% and recorded an intraday range of $0.34 - $0.42. Delcath Systems Inc.'s shares have gained 13.72% in the previous three trading sessions, 11.91% in the last one month, and 37.53% on YTD basis. The company's stock is trading above its 50-day moving average. Delcath Systems Inc.'s 200-day moving average of $0.35 is above the 50-day moving average of $0.32. Furthermore, the stock is trading at an RSI of 58.43. Sign up today to read free research on DCTH at:
Shares in Valeant Pharmaceuticals International Inc. edged 0.28% lower to finish the day at $140.40. The stock recorded trading volume of 0.99 million shares as compared to a three months average volume of 1.60 million shares. The stock fluctuated between $139.08 and $141.97 during the session. Valeant Pharmaceuticals International Inc.'s shares have lost 0.35% in the previous three trading sessions, and 5.14% in the last one month, while gaining 19.59% on YTD basis. The company's stock is trading above its 50-day and 200-day moving averages of $138.78 and $110.73, respectively. Moreover, the stock is trading at an RSI of 50.02. Sign up today to read free research on VRX at:
On Thursday, shares in Alkermes PLC gained 1.34%, closing the day at $47.51. The stock recorded trading volume of 1.26 million shares as compared to a three months average volume of 0.99 million shares. The stock fluctuated between $46.57 and $47.97 during the trading session. Shares of the company traded at a PE ratio of 174.03. Alkermes PLC's shares have advanced 3.64% in the previous three trading sessions and 16.85% on YTD basis, while falling by 10.29% in the last one month. The company's stock is trading below its 50-day moving average. Alkermes PLC's 50-day moving average of $48.54 is above the 200-day moving average of $37.74. Additionally, the stock is trading at an RSI of 45.16. Sign up today to read free research on ALKS at:
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-edge. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Investor-edge in this article or report according to the Procedures outlined by Investor-edge. Investor-edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.